Finance
Seaport Therapeutics Said to Raise $255 Million in IPO
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range, according to people familiar with the matter.
B
Bloomberg
April 30, 2026·1 min read
Image: Bloomberg
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range, according to people familiar with the matter.
Original article
Seaport Therapeutics Said to Raise $255 Million in IPO
Published by Bloomberg